GlobeNewswire: Samumed Contains the last 10 of 32 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T01:59:18ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/11/13/1946292/0/en/Samumed-Presents-Safety-Data-Analysis-of-Lorecivivint-for-Knee-Osteoarthritis-at-the-2019-ACR-Annual-Meeting.html?f=22&fvtc=4&fvtv=39903Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting2019-11-13T13:00:00Z<![CDATA[Data showed that lorecivivint had a safety profile similar to placebo]]>https://www.globenewswire.com/news-release/2019/10/02/1924019/0/en/Samumed-Publishes-Unique-Mechanism-of-Action-for-SM08502-in-Targeting-Gastrointestinal-Tumors.html?f=22&fvtc=4&fvtv=39903Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors2019-10-02T12:00:00Z<![CDATA[SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression through potent inhibition of CDC-like kinases (CLKs)]]>https://www.globenewswire.com/news-release/2019/07/18/1884543/0/en/Samumed-Announces-Publication-of-Preclinical-Data-Demonstrating-That-SM07883-is-a-Potential-Treatment-for-Alzheimer-s-Disease.html?f=22&fvtc=4&fvtv=39903Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimer’s Disease2019-07-18T12:00:00Z<![CDATA[SAN DIEGO, July 18, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of preclinical data demonstrating that SM07883 inhibits tau pathology and associated neuroinflammation, both of which are implicated in Alzheimer’s disease. The article titled “Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer’s disease” has been published in Aging Cell. SM07883 is a novel, small-molecule dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor currently being evaluated in a Phase 1 clinical trial (ACTRN12619000327189).]]>https://www.globenewswire.com/news-release/2019/06/19/1871126/0/en/Samumed-Doses-First-Subject-in-Phase-3-STRIDES-X-ray-Trial-of-Lorecivivint-for-the-Treatment-of-Knee-Osteoarthritis.html?f=22&fvtc=4&fvtv=39903Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis2019-06-19T12:00:00Z<![CDATA[The study will measure clinical and structural effects to assess the disease-modifying capabilities of lorecivivint The study will measure clinical and structural effects to assess the disease-modifying capabilities of lorecivivint]]>https://www.globenewswire.com/news-release/2019/05/02/1815229/0/en/Samumed-Launches-Phase-3-Lorecivivint-SM04690-Clinical-Program-in-Knee-Osteoarthritis.html?f=22&fvtc=4&fvtv=39903Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis2019-05-02T12:00:00Z<![CDATA[Pivotal STRIDES trials to be conducted to support lorecivivint as a potential disease-modifying treatment for knee osteoarthritis]]>https://www.globenewswire.com/news-release/2019/04/10/1801931/0/en/Samumed-Announces-Multiple-Presentations-at-the-19th-World-Congress-on-Osteoporosis-Osteoarthritis-and-Musculoskeletal-Diseases.html?f=22&fvtc=4&fvtv=39903Samumed Announces Multiple Presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases2019-04-10T12:00:00Z<![CDATA[Poster with new data from a recently completed phase 2b trial of SM04690 for the treatment of knee osteoarthritis highlights the effects of saline placebo injections versus sham injections Poster with new data from a recently completed phase 2b trial of SM04690 for the treatment of knee osteoarthritis highlights the effects of saline placebo injections versus sham injections]]>https://www.globenewswire.com/news-release/2019/04/04/1796996/0/en/Samumed-Doses-First-Subject-in-Phase-1-Trial-of-SM07883-a-Potential-Treatment-for-Alzheimer-s-Disease.html?f=22&fvtc=4&fvtv=39903Samumed Doses First Subject in Phase 1 Trial of SM07883, a Potential Treatment for Alzheimer’s Disease2019-04-04T12:00:00Z<![CDATA[DYRK1A Inhibition as a Potential Treatment for Alzheimer’s Disease Supported by Data Presented at International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2019)]]>https://www.globenewswire.com/news-release/2019/03/07/1749753/0/en/Samumed-to-Present-Clinical-Data-on-SM04690-at-the-American-Academy-of-Orthopaedic-Surgeons-2019-Annual-Meeting.html?f=22&fvtc=4&fvtv=39903Samumed to Present Clinical Data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting2019-03-07T13:00:00Z<![CDATA[SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that clinical data from its successful phase 2a trial of SM04690 for the treatment of knee osteoarthritis (OA) has been accepted as a poster presentation at the American Academy of Orthopaedic Surgeons (AAOS) 2019 Annual Meeting to be held in Las Vegas, from March 12-16, 2019.]]>https://www.globenewswire.com/news-release/2019/02/28/1744349/0/en/Samumed-Announces-Positive-End-of-Phase-2-Meeting-with-FDA-for-SM04690-in-Knee-Osteoarthritis.html?f=22&fvtc=4&fvtv=39903Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritis2019-02-28T13:30:00Z<![CDATA[STRIDES Phase 3 studies to commence first half of 2019 STRIDES Phase 3 studies to commence first half of 2019]]>https://www.globenewswire.com/news-release/2019/01/29/1706787/0/en/Samumed-to-Present-Novel-Biological-Targets-of-SM04690-for-Treatment-of-Knee-Osteoarthritis.html?f=22&fvtc=4&fvtv=39903Samumed to Present Novel Biological Targets of SM04690 for Treatment of Knee Osteoarthritis2019-01-29T13:00:00Z<![CDATA[Study results highlight novel drug discovery targets for the treatment of knee osteoarthritis]]>